Loading...
Stem Holdings, Inc.
STEM.CN•CNQ
Healthcare
Drug Manufacturers - Specialty & Generic
CA$0.31
CA$0.00(0.00%)

The company's financials show resilient growth, with revenue advancing from $4.06M in Q1 2023 to -$11.78M in Q4 2023. Gross profit remained healthy with margins at 100% in Q4 2023 compared to 1% in Q1 2023. Operating income hit $2.62M last quarter, sustaining a consistent -22% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $2.33M. Net income dropped to -$11.61M, while earnings per share reached $0.26. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan